The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
 
Peter C.C. Fong
Honoraria - AstraZeneca
Consulting or Advisory Role - Merck Sharp & Dome
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - Pfizer
 
Margitta Retz
No Relationships to Disclose
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); UROGENE (I)
Consulting or Advisory Role - Bristol-Myers Squibb; Kyn therapeutics
Research Funding - Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - 5 PATENTS AT UCLA FOR 5 POTENTIAL DRUGS (I)
Travel, Accommodations, Expenses - Lilly
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech
Other Relationship - Abbvie; Agios; Amgen; arGEN-X BVBA; Arno Therapeutics
 
William R. Berry
Honoraria - Bayer
Consulting or Advisory Role - Merck
Speakers' Bureau - Bayer
Research Funding - Merck
Travel, Accommodations, Expenses - Bayer; Merck
 
Emanuela Romano
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Susan Feyerabend
No Relationships to Disclose
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)
 
Henry Jacob Conter
Honoraria - Bristol-Myers Squibb; Celgene; Merck; Novartis
Consulting or Advisory Role - Lilly; Roche Canada
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Neal D. Shore
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Mark David Linch
Consulting or Advisory Role - BioNTech; Bristol-Myers Squibb; Janssen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck
 
Anthony M. Joshua
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst)
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
Helen Wu
Employment - Merck
Stock and Other Ownership Interests - Bayer; Merck
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; Dendreon; EMD Serono; Incyte; Janssen; Merck; QED Therapeutics; Seagen; Tolmar
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)